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Summary The concept that genetic changes accumulate during development and progression of cancer is
widely accepted. Frequent allelic losses at chromosome 13q have been found in hepatocellular carcinomas
(HCCs), and a known tumour-suppressor at 13ql4, the retinoblastoma (RB) gene, is thought to be the target
of those events. However, no strong evidence has emerged to support a significant role of RB during
hepatocarcinogenesis. To investigate the minimal area(s) of loss on chromosome 13q in HCCs, we analysed
DNAs isolated from 92 tumours for loss of heterozygosity (LOH) at 13 loci on chromosome 13q, using
polymorphic microsatellite markers. In 30 (32.6%) of 92 cases we detected LOH for at least one locus on
chromosome 13q and 20 revealed a partial or interstitial deletion of chromosome 13q. Deletion mapping of
these 20 tumours indicated two separate commonly deleted regions: one was located in the region including
RB and the other was located in the region including the BRCA2 locus. These findings suggest that at least
one putative tumour-suppressor gene for HCC other than RB, possibly BRCA2, exists on chromosome 13q.
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The genesis of human cancers is generally a multistep process
reflecting cumulative genetic alterations that include activa-
tion of oncogenes or inactivation of tumour-suppressor
genes. We and others have reported losses of heterozygosity
in hepatocellular carcinomas (HCCs) and implied the
presence of tumour-suppressor genes on chromosomes lp,
4q, 5q, 8p, lIp, 13q, 16q and 17p (Wang and Roger, 1988;
Buetow et al., 1989; Tsuda et al., 1990; Ding et al., 1991;
Fujimori et al., 1991; Murakami et al., 1991; Simon et al.,
1991; Walker et al., 1991; Emi et al., 1992, 1993; Nishida et
al., 1992; Sugimura, 1992; Yeh et al., 1994). However, the
precise molecular mechanism of development and/or progres-
sion of HCCs still remains unclear.
LOH on chromosome 13q has been observed frequently in
primary cancers of the lung (Weston et al., 1989), breast (Lee
et al., 1988), bladder (Cairns et al., 1991), ovary (Sato et al.,
1991) and liver (Wang and Roger, 1988; Murakami et al.,
1991; Walker et al., 1991; Nishida et al., 1992). The RB gene,
a gene responsible for retinoblastoma, located at 13q14, is
thought to be the most likely candidate involved in the
carcinogenesis of these cancers. However, one report has
suggested that the RB gene is probably not the target of the
frequent allelic deletions on chromosome 13q in ovarian
cancers (Kim et al., 1994). Zhang et al. (1994) also reported
infrequent somatic mutation of the RB gene in HCCs
although nearly half of tumour cells lacked the RB protein.
Recently, linkage analysis of families carrying hereditary
breast cancer localised a second gene responsible for familial
breast cancer (BRCA2) to 13ql2-13 (Wooster et al., 1994).
Those results indicated the presence of a putative tumour-
suppressor gene other than RB on the long arm of
chromosome 13; this unidentified gene might be involved in
carcinogenesis of cancers of several tissues, including HCCs.
To define the location of the putative tumour-suppressor
gene(s) on 13q, we examined deletion mapping studies of 92
HCCs using highly polymorphic microsatellite markers. Here
we present evidence that loss of heterozygosity occurs in two
discrete regions of this chromosomal arm.
Materials and methods
Tumours and DNA preparation
Primary HCCs and corresponding non-cancerous liver tissues
were obtained from 92 patients during surgery. Part of each
tissue was fixed with formalin and embedded in paraffin for
histological examination; the remaining moiety was stored at
-80C for preparation of DNA. Frozen tissue samples were
ground to a fine powder in liquid nitrogen, suspended in lysis
buffer, treated with proteinase K, and extracted by phenol-
chloroform-isoamyl alcohol as described elsewhere (Sato et
al., 1990).
LOH analysis
All 13 markers used in the present study represented
polymorphic CA-repeat microsatellite markers: D13S217,
D13S260, D13S267, D13S218, D13S263, D13S126, D13S270,
D13S172, D13S269, D13S170, D13S265, D13S159 and
D13S158 (Gyapay et al., 1994; Wooster et al., 1994; Zhang et
al., 1994). Each was amplified by the polymerase chain reac-
tion (PCR) in 10jil volumes of a mixture containing
1 x PCR buffer (6.7 mM Tris, 16.6 mM ammonium sulphate,
6.7 gAM EDTA, 10 mM P-mercaptoethanol), 20 pmol each of
unlabelled primer and primer labelled with [y-32P]ATP, 20 ng
of genomic DNA, 0.1 U of Taq DNA polymerase, 250gM of
each deoxynucleotide triphosphate and 5 mM magnesium
chloride. Reactions were performed in 25 cycles under the
following conditions: 30 s at 94°C, 30 s at 50-55°C and 30 s
at 72°C (Gene Amp PCR 9600 System, Perkin Elmer Cetus).
A 5ftl volume of each solution was denatured and then
electrophoresed in 6% polyacrylamide gel containing 7.7 M
urea and 32% formamide. Gels were fixed in 5% meth-
anol-5% acetic acid, dried and exposed to X-ray film for
8-24h.
Determination ofLOH
To evaluate the allelic dosage, the signal intensities of
polymorphic alleles were quantified with a Hoefer GS-300
scanning densitometer; the peak area corresponding to each
signal was calculated by electronic integration using a GS
370 one-dimensional electrophoresis data system (Hoefer
Scientific Instruments). The extent of dosage change of given
allele in HCC was calculated by division of the ratio of
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intensity of the abnormal allele to that of the normal allele in
tumour DNA by the corresponding ratio measured in non-
tumorous DNA. The amount of the tumour and correspon-
ding normal DNAs for PCR reaction was adjusted by
repeated PCR experiments. When >50% reduction in signal
intensity was detected, it was judged as loss of heterozy-
gosity.
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Figure 1 LOH analysis on chromosome 13q for two selected
HCCs. Microsatellite loci are identified below each autoradiog-
ram of paired DNAs from HCC (T) and corresponding normal
tissue (N). Case 57 shows LOH at D13S270 and retention at
D13S263 and D13S269. Case 239 shows LOH at D13S260 and
retention at D13S270.
Results
The linear order of the 13 microsatellite loci analysed for
LOH, and the RB locus, had been reported previously as
follows: centromere D13S217-Dl3S260-Dl3S267-D13S218
-D13S263-D13S126-D13S270-(RB gene)- D13S172-D13S269
-D13S170-D13S265-D13S159-D13S158 telomere (Gyapay et
al., 1994; Wooster et al., 1994; Zhang et al., 1994). Examples
of LOH at several of these loci are shown in Figure 1. All 92
tumours were informative for at least one of the loci
examined, and in 30 (32.6%) of them we detected LOH; ten
of these cases showed LOH at all informative loci examined
and 20 cases revealed partial or interstitial deletions of
chromosome 13q. Figure 2 summarises the results of LOH
analyses in these 20 HCCs. Tumour 171 retained heter-
ozygosity at the Dl3S263 locus, but showed LOHs in the
region distal to D13S126. Tumour 57 showed LOHs in the
region between the D13S263 and D13S269 loci, a region that
includes the RB locus, but retained heterozygosity for all
other informative loci. Tumours 205 and 239 showed LOHs
between D13S217 and D13S263, both located proximally to
the RB gene locus, but retained heterozygosity at all infor-
mative loci more proximal and distal to this region. Of the
tumours with partial losses at 13q, two cases (tumours 205
and 239) showed LOH at loci proximal to the RB gene locus;
two cases (tumours 57 and 171) showed LOH at loci around
the RB gene locus; and the other cases showed possible LOH
in both regions. These results indicate that two separate
regions are commonly deleted in HCCs, one between markers
D13S263 and D13S172 and the other between D13SD217
and D13S263, where the BRCA2 gene is thought to be
located (Wooster et al., 1994).
With respect to pathological data of tumours, LOH on 13q
was significantly higher in moderately or poorly differentiated
types (26 of 63 informative cases) than in well-differentiated
or early carcinomas (2 of 24 cases) (P = 0.002 by Fisher's
exact test). Similarly, LOH of 13q was higher in T3/T4
tumours (15 of 33 cases) than in TI (2 of 13 cases) or T2 (11
of 41 cases) tumours.
Discussion
The deletion map constructed in this study implies that two
separate regions on chromosome 13q contain HCC-assoc-
iated tumour-suppressor genes. The region between D13S263
and D13S172 covers a genetic distance of about 15 cM
(Gyapay et al., 1994) and includes the RB gene (Gyapay et
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Figure 2 Schematic representation of partial deletions on chromosome 13q in HCCs. Case numbers are shown above, and names
of loci at left. 0, LOH; 0, retained heterozygosity; blank space, uninformative. Two commonly deleted regions are indicated by
lines at the right; double arrowheads indicate their boundaries.
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al., 1994; Wooster et al., 1994; Zhang et al., 1994). The other
commonly deleted region is 23 cM in extent (Gyapay et al.,
1994). Although LOH on chromosome 13q is a frequent
feature of HCCs (Wang and Roger, 1988; Murakami et al.,
1991; Walker et al., 1991; Nishida et al., 1992), somatic
mutation of the RB gene seems to be rare in those tumours;
Zang et al. (1994) detected somatic mutations of RB in only
two of 13 HCCs with LOH of 13q and/or lack of RB protein
expression. Some investigators have shown that allelic losses
on chromosome 13q tend to occur more frequently in
advanced HCCs, being apparently associated with progres-
sion of the tumours (Murakami et al., 1991; Nishida et al.,
1992). Our data also supported these previous findings.
The results presented here suggest that the RB gene may
still be a candidate to play a role during the progression of
HCCs, although somatic mutation of RB so far detected in
HCCs is rare. However, some of our tumour samples
retained heterozygosity in the vicinity of the loci including
the RB gene, but had lost alleles in a more proximal region
that is likely to include BRCA2, a hereditary breast cancer
gene that has been linked to markers within a 6 cM interval
on 13ql2-13 (Wooster et al., 1994). As the majority of the
HCCs examined here lost a relatively large chromosomal
segment, including both the commonly deleted regions, it is
unclear whether LOHs in those tumours reflect inactivation
of the tumour-suppressor gene(s) in the proximal region, in
the distal region or in both regions. However, our findings
indicate that at least two genes on chromosome 13q are likely
to function as tumour suppressors in the hepatic cell.
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